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Abstract (293 words)  
Background: Never-smokers and never-drinkers patients (NSND) suffering from oral 
squamous cell carcinoma (OSCC) are epidemiologically different from smokers drinkers 
(SD). We therefore hypothesized that they harbored distinct targetable molecular alterations. 
Patients and methods: Data from The Cancer Genome Atlas (TCGA) (discovery set), Gene 
Expression Omnibus and Centre Léon Bérard (CLB) (3 validation sets) with available gene 
expression profiles of HPV-negative OSCC from NSND and SD were mined. Protein 
expression profiles and genomic alterations were also analyzed from TCGA, and a functional 
pathway enrichment analysis was performed. Formalin-fixed paraffin-embedded (FFPE) 
samples from 44 OSCC including 20 NSND and 24 SD treated at CLB were retrospectively 
collected to perform targeted-sequencing of 2,559 transcripts (HTG EdgeSeq system), and 
CD3, CD4, CD8, IDO1 and PD-L1 expression analyses by immunohistochemistry (IHC). 
Enrichment of a six-gene interferon-γ signature of clinical response to pembrozulimab (PD-1 
inhibitor) was evaluated in each sample from all cohorts, using the single sample gene set 
enrichment analysis method. Results: A total of 854 genes and 29 proteins were found to be 
differentially expressed between NSND and SD in TCGA. Functional pathway analysis 
highlighted an overall enrichment for immune-related pathways in OSCC from NSND, 
especially involving T-cell activation. Interferon-γ response and PD1 signaling were strongly 
enriched in NSND. IDO1 and PD-L1 were overexpressed and the score of response to 
pembrolizumab was higher in NSND compared to SD, although the mutational load was 
lower in NSND. IHC analyses in the CLB cohort evidenced IDO1 and PD-L1 overexpression 
in tumor cells that was associated with a higher rate of tumor-infiltrating T-cells in NSND 
compared to SD. Conclusion: The main biological and actionable difference between OSCC 
from NSND and SD lies in the immune microenvironment, suggesting a higher clinical 
benefit of PD-L1 and IDO1 inhibition in OSCC from NSND.  
Keywords: oral cancer; squamous cell carcinoma; never smokers never drinkers; immune 
microenvironment, programmed death-ligand 1, indoleamine 2,3-Dioxygenase 1 
 
Key message 
 To our knowledge, this is the first report showing that the main biological and 
actionable difference between OSCC from NSND and SD lies in the immune 
microenvironment and suggesting a higher benefit of PD-1/PD-L1 and IDO1 inhibition in 
OSCC from NSND. Our report provides a strong rational to refine personalized strategies of 
immune-modulation based on smoking and alcohol habits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 Head and Neck squamous cell carcinomas (HNSCC) are the seventh most common 
cancer worldwide and second to lung cancer as smoking-related cancer [1]. However, 10-15% 
HNSCC are diagnosed in never-smokers and never-drinkers patients (NSND). Three 
subgroups of NSND with HNSCC have been described: young to middle-aged men with 
oropharyngeal SCC, young women with oral tongue SCC (OTSCC) and elderly women with 
gingival SCC [2]. Although human papillomavirus (HPV) has been associated with the 
increasing incidence of oropharyngeal cancer in young men over the past decades [3], it is not 
involved in oral carcinogenesis [4] and therefore, does not account for the increasing 
incidence of OTSCC in young women [5]. Moreover, recent studies have not yet identified 
any other potentially oncogenic virus in oral cavity [6]. 
 Despite the fact that OSCC arising in NSND and smokers drinkers (SD) are 
epidemiologically different, recent studies emphasized that they share most common genomic 
alterations, such as TP53 and FAT1 mutations, as well as similar miRNA expression profiles 
[6-8]. However, while a fraction of HNSCC (7%) may be attributable only to alcohol drinking 
[9], information in alcohol habits is missing in those studies. Moreover, some studies 
excluded elderly people [7], which represent another well-established subgroup of NSND 
with OSCC [2, 10].  
 Herein, after careful selection of patients based on smoking and alcohol habits 
independently of patients’ age, we show in four independent cohorts that the main biological 
and actionable difference between OSCC from NSND and SD lies in the immune 
microenvironment. Notably, OSCC from NSND were characterized by the following: i-an 
enrichment of interferon-γ and PD1 signaling pathways; ii-a higher intratumor CD8+ T-cell 
infiltrate; iii-an overexpression of IDO1 and PD-L1 by tumor cells and iv-higher score of 
response to pembrolizumab. These features suggest a higher clinical benefit of PD-1/PD-L1 
and/or IDO1 inhibition in this subgroup of patients. 
 
Material and Methods 
Patients 
 Four independent cohorts including a total of 212 patients suffering from OSCC were 
established from a rigorous selection of patients based on alcohol and tobacco habits. The 
discovery cohort was identified from The Cancer Genome Atlas (TCGA). Three independent 
cohorts were used as validation cohorts: two cohorts, named GEO1 and GEO2, were 
established from GSE39366 and GSE65858 respectively, and downloaded from the “Gene 
Expression Omnibus” (GEO) repository; a third validation cohort included patients treated at 
Centre Léon Bérard cancer center (CLB, Lyon, France). Written informed consent was 
obtained from all patients from CLB and the study was approved by the institutional review 
board. 
 In each cohort, HPV-positive samples were excluded. The criteria used for selecting 
NSND and SD patients are detailed in Supplementary Table S1 and led to the inclusion of 117 
(ratio NSND/SD: 57/60), 25 (9/16), 26 (7/19) and 45 (20/25) patients from the TCGA 
(discovery set), GEO1, GEO2 and CLB (validation sets) cohorts respectively. 
 
Molecular profiling in oral samples  
 In the discovery cohort from TCGA, normalized gene-read counts generated from 
RNA-sequencing, somatic mutation and copy number alterations were downloaded using the 
TCGA2STAT R-package and cBioPortal, and were available in 114 (54 NSND; 60 SD), 47 
(21 NSND; 26 SD) and 114 (56 NSND; 58 SD) patients respectively. Normalized expression 
data of 237 proteins and phosphoproteins generated by reverse-phase protein array (level 4) 
were retrieved from The Cancer Proteome Atlas (TCPA) for 82 patients (45 NSND and 37 
SD).  
 In the three validation cohorts (GEO1, GEO2 and CLB), gene expression profiles were 
generated using microarray experiments (GEO1 and GEO2) as well as targeted-RNA 
sequencing in FFPE samples using the HTG EdgeSeq technology (CLB). Finally, array-based 
gene expression profiles of normal oral mucosa from 39 smokers and 40 never-smokers 
(GSE17913) and of 18 cell lines derived from human normal oral keratinocytes exposed or 
not to ethanol and nicotine (GSE57634). 
 Details on data processing are provided in the Supplementary Table S2. 
 
Functional pathway analysis  
 Gene expression profiles of OSCC from TCGA were compared between NSND and 
SD using the EBSeq R-package. The resulting list of transcripts was used to perform a gene 
set enrichment analysis (GSEA). The single sample gene set enrichment analysis (ssGSEA) 
was used to compute individual enrichment scores. The search tool for the retrieval of 
interacting genes/proteins (STRING) was used to build a functional network using 
differentially expressed proteins between SD and NSND after downloading data from TCPA. 
Additional and detailed methodology is provided in the Supplementary Methods. 
 
Immunohistochemistry (IHC)  
 Tissue sections (3µm thick) from 45 FFPE blocks of OSCC resected at CLB were used 
for IHC. IHC was performed using an automated immunostainer (Ventana Discovery XT, 
Roche, Meylan, France) with antibodies against PD-L1 (using clones SP142 and 28.8), CD3, 
CD8, CD4, p16, and IDO1. Antibodies and procedure is detailed in Supplementary Methods. 
PD-L1 and IDO1 expression by tumor and immune cells were evaluated blindly to clinical 
information using 1, 5 and 10% thresholds, positive internal control being represented by T-
cells and dendritic cells, respectively.  The CD3, CD4 or CD8+ T-cell infiltrate was scored as 
absent or low (i.e. low) versus moderate to marked (i.e. high), and the presence of T-cells 
within the tumor lobules or located at the interface between lobules and stroma was recorded. 
An automated image analysis of IDO1, PDL1 (clone 28.8) and CD8 immunostaining was also 
performed independently (HistoWiz Inc., NY 11226) and was compared to the evaluation by 
the pathologist. Detection of HPV6 and HPV16 was done in p16-positive tumors, using DNA 
in situ hybridization (ISH) (Supplementary Methods). 
 
Statistical analysis 
 Data statistical analysis was performed using GraphPad Prism version 6.00 (San 
Diego, SA). Unpaired Wilcoxon’s test and Fisher’s exact test were performed to compare 
continuous and categorical values respectively between SD and NSND. Disease-free survival 
(DFS) distributions were estimated using the Kaplan‐Meier method and compared with the 
log‐rank test between NSND and SD. DFS is defined for each cohort in Supplementary 
Methods. All statistical tests were two-sided, and P-values of 0.05 or less were considered to 
be statistically significant. For multiple testing, a false-discovery rate was computed in order 
to adjust P-value. 
 
Results 
OSCC in NSND are more common in elderly females and harbor less genomic 
alterations  
 Clinical and pathological characteristics of OSCC were compared between NSND and 
SD in four independent cohorts (TCGA, GEO1, GEO2 and CLB) (Supplementary Table S3). 
Markedly, female and elderly patients (>65years) were more common in NSND from TCGA 
(P<0.0001; P=0.0021), GEO1 (P=0.0003; P=0.0090), GEO2 (P=0.0138; P=0.0008) and CLB 
(P<0.0001; P=0.0006). No statistical difference in disease-free survival (DFS) was observed 
between NSND and SD (Supplementary Figure S1).  
 Overall, OSCC from NSND harbored significantly less mutations (P=0.0006; Figure 
1A) and copy number alterations (P=0.0005; Figure 1B) compared to SD. To gain more 
insight into differences in genomic profiles between NSND and SD from TCGA, somatic 
mutation of 12,783 genes as well as copy number values of 22,618 genes were compared 
between NSND and SD. While the mutational profiles were not significantly different (Figure 
1C), 46 genes presented different copy number values using a false discovery rate (FDR) < 
0.01 (Wilcoxon test). Notably, amplification of 11q13, including CCND1, was less frequent in 
NSND compared to SD (P<0.0001) (Figures 1D-E).  
 
The main biological difference between OSCC from NSND and SD lies in the immune 
microenvironment  
 In the TCGA dataset, we identified a set of 219 over-expressed and 635 under-
expressed genes in NSND compared to SD (called from now on “NSND gene set”) 
(FDR<0.05;|log2FC|>1). To validate this NSND gene set, we computed its enrichment score in 
GEO1 (n=25) and GEO2 (n=26) cohorts, as well as in 79 oral normal mucosa and 18 cell 
lines derived from normal human oral keratinocytes. The score was significantly higher in 
OSCC from NSND compared to SD in both GEO1 (P=0.0053) and GEO2 (P=0.0089) (Figure 
2A-B). Strikingly, no difference was observed in normal oral mucosa between smokers and  
non-smokers (P=0.3651) (Figure 2C), as well as in normal oral keratinocytes treated with 
ethanol and/or nicotine versus untreated ones (Kruskall-Wallis; P=0.2667; Supplementary 
Figure 2). These results indicate that the difference we report in OSCC affecting NSND 
versus SD patients is not related to the effect of smoking and/or alcohol on normal mucosa or 
keratinocytes. 
 In order to gain more insight into the biological differences between NSND and SD, 
we performed a GSEA in the TCGA cohort. With a FDR<0.05, 28 canonical pathways as well 
as 49 biological processes from GO, were significantly enriched in NSND compared to SD. 
Many of these pathways/processes were immune-related, especially involving T-cell 
activation and differentiation. Markedly, OSCC from NSND were also strongly enriched for 
pathways related to interferon-γ and PD1-signaling (Figure 2D).  
 The expression of 237 proteins and phosphoproteins was compared between NSND 
and SD from TCPA, which resulted in the identification of 29 proteins differentially expressed 
(Wilcoxon, FDR<0.05). Using the STRING tool, 27 of them were interconnected in a 
functional network (Figure 2D) characterized by an enrichment for 519 biological processes 
from GO (FDR<0.05), especially for immune response-regulating processes such as 
“regulation of immune system process” (FDR<0.0001) and “regulation of lymphocyte 
activation” (FDR=0.0003).  
 Since our results pointed to the importance of the immune context in OSCC from 
NSND, we computed the enrichment score of 526 immune modules in the TCGA cohort. 
Each module has been previously described as a set of transcripts whose expression was most 
associated with a selected marker gene used to name the module [11]. The score of 150 
modules was significantly different between NSND and SD (P<0.05) with 146/150 being 
higher in NSND. Using the previously published annotation for each module, the 25 most 
significant modules (Figure 2E) were related to interferon response and T-cells, such as the 
CD274 (alias PD-L1) module with a higher score in NSND (P=0.0048). 
 
Overexpression of IDO1 and PD-L1, increased tumor-infiltrating CD8+ T-cells and 
higher score of response to pembrolizumab are features of OSCC from NSND 
 In the discovery cohort (TCGA), IDO1 (FDR<0.0001) and PD-L1 (FDR=0.0038) 
were overexpressed in NSND compared to SD. Of note, PD-L1 was also overexpressed in 
NSND at protein level (P=0.0152). Consistently, IDO1 was significantly overexpressed in 
NSND compared to SD in GEO1 (P=0.0080) and GEO2 (P=0.0476) whereas PD-L1 was 
statistically overexpressed in NSND in GEO1 (P=0.0116) but not in GEO2 (P=0.2086) 
(Figures 3A-B).  
 These immune-related differences between NSND and SD were further validated in 
the CLB cohort using targeted RNA-sequencing of 2,559 genes (HTG) as well as 
immunohistochemistry (IHC). Among the 5 tumors found to be p16 positive, one was HPV-
positive by in situ hybridization and was therefore excluded from the analysis. Moreover, 
three SD samples did not pass HTG quality control and one NSND sample did not generate 
sufficient product to sequence, resulting in 44 and 40 samples for IHC and HTG data analysis 
respectively. IDO1 and PD-L1 were found to be overexpressed in NSND (P=0.0022 and 
P=0.0017 respectively) (Figures 3A-B). Expression of IDO1, PD-L1, CD3, CD4, and CD8 
was then evaluated by IHC (Supplementary Table S4; Figure 4). Using a 1% expression 
threshold to define PD-L1-positive samples, we observed a significant overexpression of PD-
L1 in tumor cells in NSND compared to SD (clone Sp142: P=0.0270; clone 28.8: P=0.0144). 
Of note, PD-L1-positive immune cells were mostly adjacent to tumor cells expressing PD-L1. 
Interestingly, two patterns of strong IDO1 staining (>10%) were observed in OSCC: some 
tumors had a strong and homogenous staining (NSND: 40% versus SD: 0%) whereas in other 
tumors, a strong staining was only found in delimited areas of the tumor (NSND: 60% versus 
SD: 17%) with a co-localization of IDO1-positive dendritic cells. Using these two patterns to 
identify IDO1-positive samples, IDO1 was overexpressed in tumors from NSND compared to 
SD (P=0.0046). Scoring the T-cell infiltrate as low versus high, high scores were more 
common in tumors from NSND for CD3 (P=0.0112), CD4 (P=0.0154) and CD8 (P=0.0285), 
while no significant difference was found in peritumor areas. This evaluation was validated by 
an automated image analysis (Supplementary Figure S3-4). 
 The association of co-overexpression of PD-L1/IDO1 with a high T-cell infiltrate 
suggested a higher clinical benefit of PD1/PD-L1 blockade in NSND [12, 13]. Thus, we 
computed the enrichment score of a six-gene response signature to pembrolizumab in HNSCC 
[14], in the four independent cohorts (Figure 3C). Interestingly, scores were higher in NSND 
compared to SD in TCGA (P=0.0012); GEO1 (P=0.0271); GEO2 (P=0.0181) and CLB 
cohorts (P=0.0002). 
 
Discussion 
 Immunotherapy is providing unprecedented advances in management of HNSCC [12, 
14, 15] but the challenge is now to understand in which clinical setting to use these agents in 
order to provide greater clinical benefit for patients [16]. Herein we report that HPV-negative 
OSCC in NSND is molecularly distinct from the disease affecting SD and is mainly 
characterized by its immune microenvironment. Notably, a significant enrichment for 
interferon-γ and PD1 pathways, an overexpression of IDO1 and PD-L1 as well as a higher 
CD8+ T-cell tumor infiltrate were observed in NSND compared to SD. Altogether, these 
features provide a strong rational for immunotherapy in NSND with OSCC, especially by 
targeting PD-L1 and IDO1. 
 Using a functional pathway analysis based on gene and protein expression to identify 
actionable pathways in NSND, we observed a significant enrichment in immune-related 
pathways in NSND compared to SD, especially involving T-cell signaling, which was 
consistent with a higher rate of tumor infiltrating T-cells in NSND, including mostly T-
cytotoxic CD8 cells. Immunologic changes induced by smoking are various and complex 
[17]. They may play a role during oral carcinogenesis through the inhibition of Langerhans 
cells maturation, by impairing T-cell recruitment and activation via the abrogation of their 
antigen presentation capability to CD4+ T cells [18], which is consistent with our result. In 
contrast, a higher rate of infiltrating CD8+ T-cells have been associated with smoking in other 
tumor settings, including non-small cell lung cancers [19]. These conflicting results across 
tumor types underlines that the effect of smoking on immunity response may depend on many 
variables including the tissue of origin [17]. Moreover, alcohol, a recognized risk factor for 
oral cancer but not for lung cancer [20], may also affect with the immune system and explain 
the differences between tumor types [21].  
 In line with the increased interferon-γ activation previously observed in HNSCC from 
NSND [22], we observed that OSCC from NSND were strongly enriched for IFN-γ response.  
In our study, we focused on IDO1 and PD-L1, both induced by IFN-γ, because they are 
targetable and were consistently overexpressed in NSND in several cohorts, at the RNA and 
protein levels. IDO1 is an enzyme involved in tryptophan catabolism, resulting in an 
immunosuppressive local environment. Overexpression of IDO1 is a mechanism of immune 
escape [23] and ID01 inhibition may exert antitumor effects via the activation of anticancer 
immunosurveillance [24]. Elevated expression of IDO1 has been also observed in pre-
treatment melanomas from responding patients to PD-L1 inhibition [13]. Together with our 
results, these observations suggest a rational for combination therapies in OSCC from NSND. 
 The higher rate of tumor infiltrating T-cells especially T-CD8, the overexpression of 
PD-L1 and IDO1 and the enrichment of IFN-γ transcriptomic signatures observed in OSCC 
from NSND, are features that have also been reported as predictors of response to PD1/PD-L1 
inhibitors [12]. The lower mutational load in NSND versus SD is expected and linked to the 
absence of exposure to carcinogenic effects of tobacco and alcohol. This might appear 
conflicting with the results of our study [12]. However, recent observations in melanomas 
indicate that a relatively low mutational load does not preclude a tumor response to PD1/PD-
L1 inhibition [25]. In a recent study, non-synonymous mutational burden did not correlate 
with response to PD-1 blockade in patients with HNSCC treated by PD-1 blockade [26]. 
While the mutational load may contribute to the clinical response to immunotherapy through 
neo-antigen-specific T cell responses, this is not always the case [27]. HPV-positive HNSCC 
harbor fewer mutations [28] and present a higher response to anti-PD1 when compared to 
HPV-negative HNSCC [14, 15, 29]. In the case of viral-induced carcinogenesis, viral antigens 
likely represent dominant antigens that stimulate T-cells reactivity and contribute to the 
inflamed tumor phenotype and IFN-γ activation. These events are predictive of response to 
PD1/PDL1 blockade, without the need for mutation-derived neoantigens [30]. Thus, as 
observed in HPV-related diseases, we may suggest that the potent IFNγ mediated immune 
response in HPV-negative OSCC from NSND is linked to a dominant tumor antigen 
independent from the mutation load.  
 In addition to genomic-based biomarkers, immune signatures of response to PD1/PD-
L1 inhibition have been recently proposed [25, 31]. In particular, a six IFN-γ-related genes 
signature of response to pembrozulimab has been established in metastatic HNSCC [14]. 
Using the HTG technology, that allows the generation of targeted gene expression profiling 
from a single FFPE section, we were able to show that this signature was significantly 
enriched in OSCC from NSND compared to SD, strengthening the potential benefit of 
PD1/PD-L1 inhibition in NSND. 
  In conclusion, the main biological and actionable difference between OSCC from 
NSND and SD lies in the immune microenvironment. Markedly, OSCC in NSND are 
characterized by an enrichment of interferon-γ and PD1 pathways, a higher intratumor T-cell 
infiltrate, an overexpression of IDO1 and PD-L1, and higher score of response signature to 
pembrolizumab. More studies are required to evaluate the impact of smoking and alcohol 
status on response to PD1/PD-L1 pathway inhibition. 
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Figure legends 
Figure 1: Genomic-profiles of OSCC in patients NSND versus SD. The mutation count (A) 
and the fraction of copy number alterations per sample (B) in OSCC from NSND and SD 
were compared in the TCGA cohort (Mann Whitney test). (C) The mutation status of genes 
commonly mutated is shown in each sample. Genes were selected based on an overall 
mutation frequency >10% in head and neck cancer from TCGA. (D) Copy number alterations 
established from GISTIC algorithm are shown for genes included in the 11q13 chromosomal 
region. (E) A Fisher-exact test was performed to compare the number of CCND1 
amplification between NSND and SD. Abbreviations: OSCC: oral squamous cell carcinomas; 
NSND: never-smokers never-drinkers; SD: smokers drinkers; TCGA: The Cancer Genome 
Atlas. 
 
Figure 2: Functional pathway analysis in OSCC. (A-C) The enrichment score of the NSND 
gene set (defined in TCGA by 219 and 635 over- and under-expressed genes respectively in 
OSCC from NSND), was computed in two independent cohorts of OSCC [(A) GSE39366 and 
(B) GSE65858], as well as in a set of normal oral mucosa (GSE17913) (C); the score was 
compared in NSND versus SD using a Mann Whitney test. (D-E) In the TCGA cohort, NSND 
were characterized by a significant enrichment for the interferon-γ and PD1 signaling 
pathways using GSEA (D) as well as a functional network including 27 of 29 proteins 
differentially expressed between NSND and SD using STRING (E). (F) Functional immune 
landscape of OSCC in NSND and SD: the enrichment score for 526 different immune 
modules [11] was computed using ssGSEA  and were compared between NSND and SD from 
TCGA. The 25 most significant modules differentially enriched and their annotation (NK, T-
cell, myeloid, interferon) are shown. Abbreviations: OSCC: oral squamous cell carcinomas; 
NSND: never-smokers never-drinkers; SD: smokers drinkers; S: smokers, NS: non-smokers; 
GSEA: gene set enrichment analysis; ssGSEA: single sample GSEA; STRING: search tool 
for the retrieval of interacting genes/proteins; TCGA: The Cancer Genome Atlas; NSND 
score: enrichment score of the NSND gene set. 
 
Figure 3: OSCC from NSND are characterized by an overexpression of IDO1, PD-L1 
and higher score of response to pembrolizumab. IDO1 (A) and PD-L1 (B) expression are 
compared between NSND and SD patients in the TCGA discovery cohort and three validation 
series including GSE39366 and GSE65858 ( array-based expression profiles) and the CLB 
cohort using the HTG EdgeSeq technology (Mann Whitney test). (C) In all four cohorts, we 
used the ssGSEA tool in order to compute an enrichment score of a six-gene response 
signature to pembrolizumab described in HNSCC [14]
 
(score called Pembro S.). Tumors were 
ranked according to this score. IDO1 and PDL1 expression are shown in all cohorts. 
Additionally, the expression of PDL1 at protein level (as determined by RPPA), the mutation 
count (MUT. Count) and the percentage of copy number alteration (% CNA) are shown in 
TCGA as well as IHC data for PDL1, IDO1, CD3, CD4 and CD8, in CLB cohort. We used 1 
and 10% thresholds to define PD-L1 and IDO1-positive samples respectively. The CD3, CD4 
and CD8+ T cell infiltrate was scored as low (-) versus high (+). Abbreviations: OSCC: oral 
squamous cell carcinomas; NSND: never-smokers never-drinkers; SD: smokers drinkers; 
TCGA: The Cancer Genome Atlas; CLB: Centre Léon Bérard; IHC: immunohistochemistry; 
ssGSEA: single sample Gene Set Enrichment Analysis; RPPA: reverse phase protein array 
 
Figure 4: IDO1, PD-L1 and CD3 expression in the CLB cohort by 
immunohistochemistry. (A-D) Well differentiated OSCC in a NSND patient; (A) 
Hematoxylin and Eosin stain (original magnification x 100); (B) PD-L1 expression by tumor 
cells and surrounding immune cells (SP142 clone; immunoperoxydase, x 100); (C) CD3 
immunostaining of stromal T cells, at the interface between lobules and stroma and within the 
lobules  (2GV6 clone; immunoperoxydase, x 100); (D) IDO1 expression by tumor cells and 
dendritic cells (4.16H1 clone; immunoperoxydase, x 100). (E-H) Well differentiated OSCC in 
a SD patient; (E) Hematoxylin and Eosin stain (original magnification x 100); (F) PD-L1 
expression by less than 1% of tumor cells and immune cells (SP142 clone; 
immunoperoxydase, x 100); (G) CD3 expression by T cells, mainly located at the periphery of 
the lobules (2GV6 clone; immunoperoxydase, x 100); (H) IDO1 expression by very rare 
dendritic cells and no tumor cells (4.16H1 clone; immunoperoxydase, x 100). Abbreviations: 
OSCC: oral squamous cell carcinomas; NSND: never-smokers never-drinkers; SD: smokers 
drinkers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure legends 
 
Supplementary Figure S1: Disease-free survival (DFS) of NSND and SD patients treated 
for OSCC, in four independent cohorts including the TCGA (discovery cohort), GEO1, 
GEO2 and the CLB cohort (validation cohorts). In all datasets, disease-free survival (DFS) 
distributions were estimated using the Kaplan‐Meier method and compared with the log‐rank 
test between NSND and SD. Abbreviations: OSCC: oral squamous cell carcinomas; NSND: 
never-smokers never-drinkers; SD: smokers-drinkers; TCGA: The Cancer Genome Atlas; 
CLB: Centre Léon Bérard.  
 
Supplementary Figure S2: Score of the NSND gene set in 18 cell lines derived from 
human normal oral keratinocytes. The enrichment score of the NSND gene set was 
computed in 18 cell lines derived from human normal oral keratinocytes treated with various 
doses of ethanol and/or nicotine. Cell lines were divided in four groups: “Eth- Nicot-”: 
controls not treated; “Eth- Nicot+”: not treated by ethanol but treated by various doses of 
nicotine; “Eth+ Nicot-”: treated by various doses of ethanol but not by nicotine; “Eth+ 
Nicot+”: treated by various doses of ethanol and nicotine. Scores were compared between the 
four groups, using a Kruskall-Wallis test. 
 
Supplementary Figure S3: Automated image analysis and evaluation by the pathologist 
of IDO1, PDL1 (clone 28.8) and CD8 immunostaining in the CLB cohort. For each 
antibody, the percentage of positive staining cells (automated image analysis) was compared 
between samples classified by the pathologist, using a Mann-Whitney test. In order to identify 
positive or negative samples, the thresholds used by the pathologist were 1% and 10% 
(diffuse or local) for PDL1 (28.8) and IDO1 respectively. For CD8, samples were classified as 
LOW (no or low infiltrate) or HIGH (moderate to marked infiltrate). 
NEG: negative; POS: positive 
 
Supplementary Figure S4: Expression of IDO1, PDL1 and CD8 at RNA (targeted 
RNASeq) and protein (immunohistochemistry) level in the CLB cohort. Using a Mann 
Whitney test, the expression of PDL1, IDO1 and CD8 (HTG Edge Seq technology) was 
compared between positive/high and negative/low samples for immunostaining of antibodies 
corresponding to these genes, as evaluated by the pathologist. The thresholds used by the 
pathologist were 1% and 10% (diffuse or local) for PDL1 (28.8) and IDO1 respectively. For 
CD8, samples were classified as LOW (no or low infiltrate) or HIGH (moderate to marked 
infiltrate).  
NEG: negative; POS: positive 
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